Immune Activation and Drug Absorption in HIV-Infected Patients

Completed · Not applicable

Conditions studied: HIV Infection

In brief

The investigators' objective is to describe the variability of rifampicin absorption, markers of inflammation and gut damage, intestinal absorptive capacity, and intestinal permeability among HIV-infected volunteers. Rifampicin is the least well absorbed of the first-line anti-tuberculosis drugs. Rifampicin malabsorption is frequently observed in HIV-infected patients with active tuberculosis, but cannot be predicted by patient factors such as CD4+ T cell count, viral load, or the presence of diarrhea. The mechanisms for rifampicin malabsorption in HIV-infected patients are unknown. An understanding of mechanisms for rifampicin malabsorption could eventually lead to new therapeutic targets, with the ultimate goal of improving HIV/tuberculosis treatment outcomes.

Key facts

Study ID

NCT01845298

Run by

Drexel University

People needed

7

Starts

2014-06-01

Expected to finish

2016-03-14

Last updated by the study team

2017-03-03

Who can join

Age: 21 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV-infected males and females, between the ages of 21 and 45 years.
• Naïve to antiretroviral therapy
• T cell count greater than 350 cells/mm3
• Body Mass Index (BMI) greater or equal to 19 and less than or equal to 33.
• Weight greater than 60 kilograms.
• Ability and willingness to provide informed consent.
• Ability to swallow oral medications

You may not qualify if…

• Breastfeeding.
• Allergy or sensitivity to rifampicin.
• Prior history of documented active tuberculosis infection.
• Receipt of any investigational therapy, chemotherapy, or immune modulatory agents within 42 days prior to study entry.
• The following laboratory values obtained within 42 days prior to study entry:
• Hemoglobin < 12.0 g/dL; Females: Hemoglobin < 11.0 g/dL Platelet count < 100,000/mm3 AST, ALT, and bilirubin > 5x ULN An estimated creatinine clearance < 80 mL/min based on the Cockroft-Gault equation
• Positive blood test for latent tuberculosis infection (T-SPOT)
• Female participants of reproductive potential must have a negative serum or urine pregnancy test performed with 28 days prior to study entry.
• "Female participants of reproductive potential" is defined as women who have reached menarche or who have not been post-menopausal for at least 24 consecutive months (i.e. who have had menses within the preceding 24 months) or who have not undergone surgical sterilization (e.g. hysterectomy, or bilateral oophorectomy or salpingectomy).
• Female participants of reproductive potential that are using oral contraceptive pills (OCPs) must be willing to use barrier precautions for contraception for at least 7 days following each study visit.
• Use of any of the following prescription medications within 30 days prior to study entry, which may have drug-drug interactions with rifampicin, including (but not limited to):
• Anti-coagulants (warfarin)
• Cardiac drugs (digoxin, quinidine, verapamil, nifedipine, metoprolol, atenolol, carvedilol)
• Hypoglycemics (rosiglitazone, pioglitazone, glipizide, repaglinide)
• Proton pump inhibitors (omeprazole, esomeprazole,
• Immune modulators (tacrolimus, cyclosporine)
• Corticosteroids (dexamethasone, prednisone, hydrocortisone)
• H2 blockers (ranitidine, cimetidine)
• HMG CoA reductase inhibitors (atorvastatin, pravastatin, simvastatin)
• Benzodiazepines (alprazolam, diazepam, midazolam, triazolam)
• CNS-acting drugs (amitriptyline, buproprion, clozapine, phenytoin)
• Evidence of current ongoing tobacco use, illicit drug use, or average alcohol use of greater than 2 drinks per day.
• Any illness that, in the opinion of the study investigator, might confound the results of the study, or pose an additional risk to the subject by his or her participation in the study.

Where it is running

• Drexel University College of Medicine — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.